CASSANDRA KILPATRICK: Open Payments
NPI 1548748320 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$726 in 39 payments from 14 companies in 2025. Trend: 2023 $169 · 2024 $710 · 2025 $726
Food & beverage: $726
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $267 |
| Lilly USA, LLC | 4 | $71 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $56 |
| Janssen Pharmaceuticals, Inc | 2 | $48 |
| Novo Nordisk Inc | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| PFIZER INC. | 2 | $35 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $33 |
| ABIOMED | 1 | $33 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
Products named: VRAYLAR, QULIPTA, JARDIANCE, SPRAVATO, REXULTI, XIFAXAN, Wegovy, GIVLAARI.
Industry payments across NE — which companies pay providers there.
